Changes of wind direction, wind speed and specific <i>orf2</i> amplicons during typhoon events for a range of years (2019–2020, n by Kuang-Yueh Chen (21071954)

Data Sheet 1_Adjunctive esketamine in propofol-based sedation for gastrointestinal endoscopy: a systematic review and meta-analysis of randomized trials.docx by Jiazheng Qi (22679312)

“…No significant differences were found for hypertension, arrhythmias, PONV, recovery time or dizziness.…”

S1 Graphical abstract - by Huimin Xian (20390006)

“…</p><p>Conclusions</p><p>In patients with MVD-STEMI, the incidence of MACEs was lower in FCR than in FIR, and the decrease was particularly significant in the DM cohort. …”

Procedural characteristics. by Huimin Xian (20390006)

“…</p><p>Conclusions</p><p>In patients with MVD-STEMI, the incidence of MACEs was lower in FCR than in FIR, and the decrease was particularly significant in the DM cohort. …”

Clinical characteristics. by Huimin Xian (20390006)

“…</p><p>Conclusions</p><p>In patients with MVD-STEMI, the incidence of MACEs was lower in FCR than in FIR, and the decrease was particularly significant in the DM cohort. …”

Study flowchart. by Huimin Xian (20390006)

“…</p><p>Conclusions</p><p>In patients with MVD-STEMI, the incidence of MACEs was lower in FCR than in FIR, and the decrease was particularly significant in the DM cohort. …”

Data. by Huimin Xian (20390006)

“…</p><p>Conclusions</p><p>In patients with MVD-STEMI, the incidence of MACEs was lower in FCR than in FIR, and the decrease was particularly significant in the DM cohort. …”

Table 1_Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study.xlsx by Yujuan Wu (2249857)

“…Background<p>Peripheral immune cells can predict responses to immune checkpoint inhibitor (ICI) therapy, but their relationship with early ICI-associated cardiovascular adverse events (CVAEs) is unclear. This study aimed to assess the predictive value of peripheral immune cells in early ICI-associated CVAEs.…”

Table 2_Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study.docx by Yujuan Wu (2249857)

“…Background<p>Peripheral immune cells can predict responses to immune checkpoint inhibitor (ICI) therapy, but their relationship with early ICI-associated cardiovascular adverse events (CVAEs) is unclear. This study aimed to assess the predictive value of peripheral immune cells in early ICI-associated CVAEs.…”

Image 1_Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study.tif by Yujuan Wu (2249857)

“…Background<p>Peripheral immune cells can predict responses to immune checkpoint inhibitor (ICI) therapy, but their relationship with early ICI-associated cardiovascular adverse events (CVAEs) is unclear. This study aimed to assess the predictive value of peripheral immune cells in early ICI-associated CVAEs.…”

Image 2_Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study.tif by Yujuan Wu (2249857)

“…Background<p>Peripheral immune cells can predict responses to immune checkpoint inhibitor (ICI) therapy, but their relationship with early ICI-associated cardiovascular adverse events (CVAEs) is unclear. This study aimed to assess the predictive value of peripheral immune cells in early ICI-associated CVAEs.…”

Image 3_Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study.tif by Yujuan Wu (2249857)

“…Background<p>Peripheral immune cells can predict responses to immune checkpoint inhibitor (ICI) therapy, but their relationship with early ICI-associated cardiovascular adverse events (CVAEs) is unclear. This study aimed to assess the predictive value of peripheral immune cells in early ICI-associated CVAEs.…”

Table 2_Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases.xlsx by Xianyu Dai (18939514)

“…The median age among these cases was 65 years, with males comprising 53.4%. There were significant annual increases in UR reports associated with antineoplastic agents (0.19% per year) and antidiabetic drugs (0.09% per year), while reports linked to bronchodilators decreased (−0.53% per year). …”

Table 1_Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases.docx by Xianyu Dai (18939514)

“…The median age among these cases was 65 years, with males comprising 53.4%. There were significant annual increases in UR reports associated with antineoplastic agents (0.19% per year) and antidiabetic drugs (0.09% per year), while reports linked to bronchodilators decreased (−0.53% per year). …”

Trial design. by Llum Páez (22553360)

“…Vaccination against canine leishmaniasis intends to decrease the parasite burden and the risk of clinical disease. …”

Schedule of the trial. by Llum Páez (22553360)

“…Vaccination against canine leishmaniasis intends to decrease the parasite burden and the risk of clinical disease. …”

Clinical symptoms scoring system. by Llum Páez (22553360)

“…Vaccination against canine leishmaniasis intends to decrease the parasite burden and the risk of clinical disease. …”

Marketed vaccines against canine leishmaniasis. by Llum Páez (22553360)

“…Vaccination against canine leishmaniasis intends to decrease the parasite burden and the risk of clinical disease. …”

Data Sheet 1_Frailty and cardiovascular safety of JAK inhibitors versus TNF inhibitors in rheumatoid arthritis: a real-world comparative study of drug effects and patient profiles.... by Ettore Silvagni (9576002)

“…Objective<p>The aim of this study was to comparatively assess the risk of cardiovascular events (CVEs) in rheumatoid arthritis (RA) patients treated with Janus kinase inhibitors (JAKis) or tumor necrosis factor inhibitors (TNFis) and to explore the interactions with patient profiles [including age, baseline cardiovascular (CV) risk, and frailty, which is a state of decreased physiological reserve, assessed using a validated frailty index (FI) for healthcare administrative databases (AHDs)].…”

Data Sheet 2_Frailty and cardiovascular safety of JAK inhibitors versus TNF inhibitors in rheumatoid arthritis: a real-world comparative study of drug effects and patient profiles.... by Ettore Silvagni (9576002)

“…Objective<p>The aim of this study was to comparatively assess the risk of cardiovascular events (CVEs) in rheumatoid arthritis (RA) patients treated with Janus kinase inhibitors (JAKis) or tumor necrosis factor inhibitors (TNFis) and to explore the interactions with patient profiles [including age, baseline cardiovascular (CV) risk, and frailty, which is a state of decreased physiological reserve, assessed using a validated frailty index (FI) for healthcare administrative databases (AHDs)].…”